Several novel treatment agents for myeloproliferative neoplasms are currently being studied in phase 1 or phase 2 trials.
Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.
Researchers are assessing the value and safety of discontinuing TKI therapy in patients with chronic phase CML who have achieved deep molecular response.
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
In a review article, researchers discussed maintenance treatment strategies using chemotherapy, immunotherapy, targeted small molecules, and more.
Due to conflicting literature, there is currently no consensus on the appropriate standard of care for managing polycythemia vera.
Myelodysplastic syndromes display a high degree of heterogeneity, making it difficult to establish a standard of care for patients.
As oncologists welcome new chronic lymphocytic leukemia treatments, one researcher creates a scoring system to make the case for transplants.
The American Society of Clinical Oncology released updates to their guidelines for thromboprophylaxis in patients with cancer.
Second-line treatment strategies for severe aplastic anemia include stem cell transplant, immunosuppressive therapy, and thrombopoietin mimetics.
The use of real-world data shows promise in guiding the development of management strategies for lymphoid malignancies.
In a review article, researchers discussed how to maximize treatment efficacy while minimizing adverse effects for patients with mantle cell lymphoma.
Lack of resources and poor awareness of thalassemia can make it difficult for patients with beta thalassemia to receive necessary blood transfusions.
Oncology nurses discuss the importance of ongoing education on the treatments, symptoms, and available information on MPNs for patients, and oncology nurses.
New studies in morbidly obese patients suggest that direct oral anticoagulants may be a safe and efficacious treatment option for thromboembolism and atrial fibrillation.
Researchers highlighted the current status of diagnostic strategies and laboratory screening tests for von Willebrand disease.
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
Both autologous and allogeneic stem cell transplantation have shown benefits in patients with relapsed follicular lymphoma, but long-term data are lacking.
Combining caplacizumab with therapeutic plasma exchange could decrease hospital stays and treatment costs in the long term.
Group O Rh(D)-negative blood cells can be administered to patients with any ABO Rh(D) type, making them a valuable but limited resource.
In addition to current obinutuzumab- and rituximab-based treatment regimens, several novel agents have received approval for follicular lymphoma treatment.
Current treatment strategies for immune thrombocytopenic purpura are centered on immunomodulation and decreasing platelet destruction
Many clinical and ethical factors influence whether preemptive transplant would be beneficial for patients genetically predisposed to acute myeloid leukemia.
Though lymphoproliferative diseases during pregnancy can lead to complications, a host of treatment options exists.
Treatment strategies for children with hemophilia who have inhibitors should involve eradicating the inhibitor and managing bleeding.
In a review, researchers discussed the value of combining immunotherapy, targeted therapy, and chemotherapy to improve treatment for double hit lymphoma.
Therapeutic plasma exchange could become an effective mainstay of treatment for immune-mediated thrombotic thrombocytopenic purpura.
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
Results from ongoing trials suggest targeted therapy may improve survival outcomes in acute myeloid leukemia, but further research is needed.
Currently, molecular testing occurs at the tail end of the diagnostic workflow for inherited bleeding disorders.
Variation in disease phenotype and clinical circumstances makes it difficult to create a standardized treatment approach to von Willebrand disease.
Patients with atrial fibrillation and cancer may be at higher risk for thromboembolic events.
Identifying patients with smoldering myeloma at high risk for disease progression may allow for implementation of better treatment strategies.
Proteasome inhibitors and immunomodulatory drugs have demonstrated improvements in survival and response in patients with multiple myeloma.
Many CML patients on TKI treatment report muscle complaints, but there has been little work to find out why. A new study sought to find out more about the nature of these complaints and to undercover a biological mechanism to explain them.
Investigators estimated the effects of immunosuppression on poor outcomes in multiple cutaneous squamous cell carcinoma.
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Advances in treatment options for acute myeloid leukemia may replace currently accepted induction regimens as the standard of care.
Treatment with erythropoietin-stimulating agents may yield improved hematopoietic responses and reduce the need for red blood cell transfusions.
A variety of immune pathways mediate the pathogenesis of myelodysplastic syndromes, suggesting that the immune system may be a feasible therapeutic target.
Bruce Levine, PhD, explains why targeting multiple antigens simultaneously may be the most promising approach for adoptive cell therapies such as CAR-T.
Though adoptive T-cell transfer has demonstrated clinical applicability, many barriers prevent it from becoming a standard of care following transplant.
In this review, researchers discussed strategies for identifying and treating infection in patients undergoing intensive chemotherapy.
The presence of measurable residual disease may be a reliable predictor of relapse in patients with acute myeloid leukemia.
High shear stress in blood vessels due to cardiovascular disease may be associated with the development of acquired von Willebrand syndrome.
Because most studies on heavy menstrual bleeding have been conducted in adults, treatment guidelines for adolescents are lacking.
Integrating mutation-specific data across repositories and portals may lead to novel therapeutically actionable insights for acute myeloid leukemia.
Treatment for lymphoblastic lymphomas may result in high morbidity and poor prognosis, highlighting the need for novel targeted therapeutic approaches.